Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ruvise

- PMLiVE

AVEO warns EU approval of Fotivda could be at risk

Concerns arose with overall survival data

Novartis day

Novartis claims first place for psoriasis drug Cosentyx in China

Trial data from China helped support filing

- PMLiVE

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Acquires its portfolio of NLRP3 targeting drugs

- PMLiVE

FDA approves Novartis’ next-gen MS drug Mayzent

Drug reduces risk of disease progression

- PMLiVE

Francis exits Sandoz, reigniting spinoff rumours

Novartis says no such plans at present

- PMLiVE

EMA could follow FDA’s Xeljanz blood clot warning

European agency in step with FDA after safety doubts

- PMLiVE

Novartis back in the spotlight over Trump/Cohen links

Cohen said the fee intended to get him to work as a lobbyist

- PMLiVE

Novartis in-licenses Akcea’s novel cardiovascular therapy

Lp(a) targeting therapy could treat millions

- PMLiVE

Greater Manchester backs move to outcome-based payment

Region teams up with Cancer Research UK to accelerate change

- PMLiVE

Xencor’s Novartis-partnered bispecific on hold after patient deaths

The two death’s included one case of CRS

- PMLiVE

Big opportunities in big data, but EMA and industry just getting started

250m genomes sequenced, but data trapped in silos

- PMLiVE

Novartis’ Egatan gains US approval for neglected tropical disease

US approval removes barrier to greater access

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links